MK-677 vs Ipamorelin: A Research Comparison
MK-677 and Ipamorelin both agonize the ghrelin receptor (GHS-R1a), so the comparison is about molecular class and route of activity, not target. MK-677 (Ibutamoren) is a non-peptide small molecule investigated as an orally active secretagogue; Ipamorelin is a selective peptide reconstituted from lyophilized powder for research. The canonical difference is small molecule versus peptide. Neither is an approved medicine, and both are supplied for research use only.
The core difference: small molecule vs peptide
Both compounds are studied as agonists of the same ghrelin receptor (GHS-R1a), so the defining distinction is what they are made of and how they behave. MK-677 (Ibutamoren) is a non-peptidic small molecule noted in research for oral bioavailability and a long duration of GHS-R activation. Ipamorelin is a five-residue peptide that must be reconstituted from lyophilized powder and is noted for selective receptor engagement. Both raise growth hormone secretion through the same receptor, but the small-molecule format is why MK-677 is studied as an orally active tool while the peptide format defines how Ipamorelin is handled.
Structure and molecular profile
MK-677 is a small molecule (free-base molecular weight near 528.7 g/mol), often supplied as the mesylate salt, and is prepared per research protocol rather than reconstituted like a peptide. Ipamorelin is a lyophilized selective pentapeptide (molecular weight near 711.9 g/mol) reconstituted with bacteriostatic water. Confirm the exact salt form of MK-677 against its Certificate of Analysis, since a small-molecule salt changes the effective mass per milligram.
Clinical and regulatory context
MK-677 (Ibutamoren) has been investigated in human clinical research as an orally active growth hormone secretagogue acting on the GH and IGF-1 axis, and Ipamorelin has likewise been evaluated in human clinical research, including a Phase 2 study in postoperative ileus. Neither has received regulatory approval as a marketed drug, and both are handled here strictly as research-use-only materials rather than therapeutic products.
How each is studied
Research with MK-677 examines the GH and IGF-1 axis and the pharmacology of a long-acting oral non-peptide secretagogue. Research with Ipamorelin isolates selective GHS-R1a signaling in a peptide. The choice usually follows format: MK-677 when the design calls for an orally active small molecule with extended receptor activation, and Ipamorelin when a short-acting, highly selective peptide better matches the question.
All products are intended strictly for in-vitro laboratory research and development use only. Not for human or veterinary use, not a drug, food, or cosmetic, and not intended to diagnose, treat, cure, or prevent any disease.